We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, quality of life, and mood.
- Authors
Attia, Albert; Rapp, Stephen R; Case, L Doug; D'Agostino, Ralph; Lesser, Glenn; Naughton, Michelle; McMullen, Kevin; Rosdhal, Robin; Shaw, Edward G
- Abstract
Ginkgo biloba has been reported to improve cognitive function in older adults and patients with Alzheimer's disease and multi-infarct dementia. We conducted an open-label phase II study of this botanical product in symptomatic irradiated brain tumor survivors. Eligibility criteria included: life expectancy ≥30 weeks, partial or whole brain radiation ≥6 months before enrollment, no imaging evidence of tumor progression in previous 3 months, or stable or decreasing steroid dose, and no brain tumor treatment planned while on study. The Ginkgo biloba dose was 120 mg/day (40 mg t.i.d.) for 24 weeks followed by a 6-week washout period. Assessments performed at baseline, 12, 24 (end of treatment), and 30 weeks (end of washout) included KPS, Functional Assessment of Cancer Therapy-Brain (FACT-Br), Profile of Mood States, Mini-Mental Status Exam, Trail Making Test Parts A (TMT-A) and B (TMT-B), Digit Span Test, Modified Rey Osterrieth Complex Figure (ROCF), California Verbal Learning Test Part II, and the F-A-S Test.
- Publication
Journal of neuro-oncology, 2012, Vol 109, Issue 2, p357
- ISSN
1573-7373
- Publication type
Journal Article
- DOI
10.1007/s11060-012-0901-9